Literature DB >> 17607373

Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.

Suash Sharma1, Mehar C Sharma, Maribeth H Johnson, Mimi Lou, Alok Thakar, Chitra Sarkar.   

Abstract

Esthesioneuroblastoma (ENB) differs from adrenal neuroblastomas in its histopathologic and biologic characteristics. Hyams grading and Kadish staging have shown correlation with survival. Scant data are available on proliferation indices and prognosis. We retrospectively reviewed the clinicopathologic characteristics of ENB. Both Kadish and UCLA staging systems were used. Hyams grading was simplified into low and high grade. DNA topoisomerase II alpha labeling index (T2alpha LI) was obtained in 8 cases using immunohistochemistry. Of the 19 cases studied, 14 were males and 5 females. Age range was 2 to 62 years (average 27 years). The mass primarily involved the nose in 12 (63%) and paranasal sinuses in 7 cases (37%). Patients presented with nose block in 19 (100%), epistaxis in 10 (53%), proptosis in 9 (47%) and loss of vision in 6 cases (32%). Bony involvement was seen in 7 cases (37%), and intracranial spread in one case (5%). Thirteen (68%) were low-grade tumors and 6 were (32%) high-grade. There was no statistically significant difference between the low- and high-grade ENB in age (years) (p=0.2882), duration of symptoms (months) (p=0.5636), and either in the Kadish (p=0.5456) or the UCLA staging system (p=0.7771). The difference in DNA topoisomerase alpha labeling index between the low- and highgrade ENB (medians: 10.4 and 22.3, respectively) was not statistically significant (p=0.0714), but it was suggestive of a positive association. The results of this study should be interpreted with caution, because of the limited sample size. Three cases recurred locally, one each stage A, B and C, but all low-grade. This preliminary study suggests the need to combine a simplified histologic grading with accurate staging in a reasonable attempt to assess local progression in esthesioneuroblastoma. Larger studies may clarify the role of T2alpha LI in improving histologic grading.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17607373     DOI: 10.1007/bf02893487

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma.

Authors:  Yuko Mishima; Eijiro Nagasaki; Yasuhito Terui; Tetsuya Irie; Shunji Takahashi; Yoshinori Ito; Masahiko Oguchi; Kazuyoshi Kawabata; Shinetsu Kamata; Kiyohiko Hatake
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

2.  [Clinical analysis of 34 cases of esthesioneuroblastoma].

Authors:  Wen-Sheng Liu; Ping-Zhang Tang; Guo-Zhen Xu
Journal:  Zhonghua Er Bi Yan Hou Ke Za Zhi       Date:  2004-06

3.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

4.  Olfactory neuroblastomas: survival rate and prognostic factor.

Authors:  Sung-Kyun Hwang; Sun-Ha Paek; Dong Gyu Kim; Yoon-Kyung Jeon; Je G Chi; Hee-Won Jung
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 5.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

6.  Esthesioneuroblastoma. Long-term outcome and patterns of failure--the University of Virginia experience.

Authors:  B V Eden; R F Debo; J M Larner; M D Kelly; P A Levine; F M Stewart; R W Cantrell; W C Constable
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

7.  Esthesioneuroblastoma: reflections of a 21-year experience.

Authors:  P A Levine; R Gallagher; R W Cantrell
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

8.  Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis.

Authors:  R C Miyamoto; L L Gleich; P W Biddinger; J L Gluckman
Journal:  Laryngoscope       Date:  2000-08       Impact factor: 3.325

9.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

10.  An ultrastructural and immunohistochemical study of olfactory neuroepithelioma with rhabdomyoblasts.

Authors:  Mitsusuke Miyagami; Yoichi Katayama; Noriko Kinukawa; Tatsuo Sawada
Journal:  Med Electron Microsc       Date:  2002-09
View more
  2 in total

1.  Esthesioneuroblastoma: one of the causes of proptosis.

Authors:  Sajid Ansari; Kaleem Ahmad; Kanchan Dhungel; Mukesh Kumar Gupta; Md Farid Amanullah
Journal:  Head Face Med       Date:  2013-07-27       Impact factor: 2.151

2.  An isolated orbital mass with proptosis and diplopia: an uncommon metastasis from intracranial olfactory neuroblastoma in a chinese patient.

Authors:  Jianqin Shen; Hongguang Cui; Shi Feng
Journal:  Onco Targets Ther       Date:  2016-08-24       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.